RESUMO
Purpose@#Clinically, breast cancer can be divided into 4 subtypes based on the presence of hormone receptors, human epidermal growth factor receptor 2 (HER2), and Ki-67. Because the pattern and time of recurrence vary according to the subtype, we evaluated whether there was a difference in overall survival (OS) among the subtypes according to the time and type of recurrence. @*Methods@#A total of 2,730 patients who underwent breast cancer surgery were analyzed. Early and late recurrence were defined as recurrence within and after 5 years of diagnosis, respectively. Recurrence type was categorized as locoregional recurrence or systemic recurrence. @*Results@#Hormone receptor-positive tumors were significantly more frequent in the late recurrence group than in the early recurrence group (estrogen receptor positive, 47.8% [early] vs. 78.7% [late]). However, there was no difference in the rate of HER2 overexpression (HER2+, 38.1% [early] vs.39.0% [late]). In subgroup analysis, early recurrence was a significant prognostic factor for OS in all subtypes. However, late recurrence was a significant prognostic factor for OS only in the luminal B subtype (hazard ratio of 4.30). In addition, the luminal B type had the highest proportion in late recurrence patients (63.2%). @*Conclusion@#The luminal B subtype had a high rate of late recurrence, and late recurrence was a poor prognostic factor for OS only in this subgroup. Therefore, further targeted treatments for luminal B breast cancer are needed and patients with this subtype require close long-term surveillance.
RESUMO
BACKGROUND: Cytokines play a key role in the regulation of cells of the immune system and also have been implicated in the pathogenesis of malignant disease. Usually malignant cells secreted various types of cytokine, and the cytokine levels have been shown to be potential for diagnosis of malignant disease. To differentiate the ovarian cancer from other benign diseases, the levels of cytokine in peritoneal fluid have been revealed more effect than those in blood. METHODS: The levels of interferon-gamma, tumor necrosis factor-alpha, interleukin-1 beta, interleukin-5, interleukin-6 and interleukin-10 in peritoneal fluid from 31 cases of ovarian cyst, 14 cases of ovarian cancer, and 20 cases of endometriosis were determined by enzyme-linked immunosorbent assay(Endogen Inc., USA). RESULTS: The mean level of interleukin-1 beta, interleukin-6, and interleukin-10 in the patients of in ovarian cancer were 10.49+/-17.44 pg/mL, 705.79+/-236.06 pg/mL and 231.56+/-145.43 pg/mL, respectively, which were significantly higher than in ovarian cyst(2.00+/-2.04 pg/mL, 103.42+/-154.49 pg/mL and 27.90+/-23.20 pg/mL, respectively)(P<0.05). The mean concentration of interferon-gamma, tumor necrosis factor-alpha, and interleukin-5 in patients of ovarian cancer were not significantly different from the benign group. CONCLUSIONS: The cytokine levels of peritoneal fluid in ovarian cancer were significantly higher than ovarian cyst and endometriosis. So, the measurement of cytokine level in neoplastic effusion could be useful to differentiate malignant from ovarian cyst.